# Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

> **NCT07543536** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 132 (estimated)

## Conditions studied

- Advanced/Metastatic Breast Cancer
- HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer

## Interventions

- **DRUG:** Megestrol Acetate + Trastuzumab Deruxtecan
- **DRUG:** Placebo + Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT07543536
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543536, "Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07543536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*